International clinical activities

Vaccine development

Malaria infection during pregnancy is a major health problem that can lead to the development of placental malaria, affecting particularly vulnerable populations of pregnant women and babies in Africa. In 2020, about 11 million pregnant women were exposed to malaria infection, which is estimated to lead to 200,000 infant deaths each year and 819,000 low birth weight infants. Placental malaria causes adverse pregnancy outcomes, including anemia, high blood pressure  and low birth weight; Issues associated with a higher risk of morbidity and mortality in fetuses and neonates. The development of an effective and affordable vaccine would be critical to efficiently reduce the incidence and severity of placental malaria and protecting the mother and unborn child during pregnancy.

Funded through the Horizon Europe research funding scheme of the European Commission this project called ADVANCE-VAC4PM aims at advancing development of two vaccine candidates against placental malaria.

While phase 1a testing will take place at our premises at Radboudumc in the Netherlands, phase 1b and phase 2 trials will be conducted in collaboration with our partners in Benin and Burkina Faso.

PRISM

Our understanding of malaria immunity and the spread of malaria infections can benefit greatly from in-depth epidemiological studies in malaria endemic countries. In Uganda, we undertake such studies with a multi-disciplinary team of researchers from the Kampala, Nijmegen, London, Liverpool and San Francisco. Our work aims to understand all aspects of malaria transmission using tools ranging from genomic surveillance to social science. Researchers from Radboudumc specifically study the development of malaria transmission stages, infectivity to mosquitoes and immune responses that can prevent mosquitoes from becoming infected. These questions are being addressed in large longitudinal studies where individuals living in malaria endemic areas in Uganda are followed for several years under natural malaria exposure. 

Funded through the US National Institutes of Health (NIH) and the European Research Council (ERC-Consolidator Grant) this project aims at supporting malaria policy in Uganda by frequent interactions with local and international policy makers.

Sleep in Malaria (SLiMA)

Funded by the German Research Foundation (DFG - Deutsche Forschungsgemeinschaft) and conducted in collaboration with an international consortium at the Centre de Recherche Médicales de Lambaréné (Gabon) we investigate the impact of malaria on sleep and how different sleep patterns affect the immune response to malaria. The effects of this interplay on sickness behavior, host defense mechanisms, the recovery process and disease will be evaluated.

Transmission networks of malaria infections

For malaria control efforts, it is important to understand who forms the source of new malaria infections. This can be done indirectly, by quantifying how infectious individuals are to mosquitoes and extrapolating the likely contribution to onward transmission. However, it can also be done more directly by studying patterns of malaria infections in space and time. In The Gambia, clinical and asymptomatic infections are being monitored over the course of several transmission seasons. Using a large panel of genetic parasite markers and information on the occurrence of malaria infections in space and time, we establish transmission networks where we identify the most likely source of newly detected infections.

Funded through the Bill & Melinda Gates Foundation and the European Research Council (ERC-Consolidator Grant) this project aims at providing evidence for international policy makers on the relative importance of asymptomatic malaria infections and low-density infections for malaria transmission.